IDH1 Mutation Biology and the 2-HG Oncometabolite
IDH1 mutations at codon R132 — including the IDH1R132C, IDH1R132H, IDH1R132S, IDH1R132G, and IDH1R132L allelic variants — are present in approximately 6–10% of AML cases and confer a neomorphic enzymatic activity: the NADPH-dependent conversion of alpha-ketoglutarate (α-KG) to 2-hydroxyglutarate (2-HG). Dang et al. first characterised 2-HG as a novel oncometabolite capable of inhibiting α-KG-dependent dioxygenases, including TET2, histone demethylases of the KDM family, and DNMT3A interactors, thereby establishing a hypermethylation state that blocks myeloid progenitor differentiation.
This epigenetic block is the mechanistic basis for the differentiation syndrome observed clinically when IDH1 inhibitors are administered: as 2-HG is suppressed, leukemic blasts resume differentiation, sometimes causing a systemic inflammatory response. Raffel et al. confirmed that IDH1 inhibitor treatment restores the differentiation capacity of leukemic blasts, providing the mechanistic rationale for this class-effect toxicity. According to NIH PubMed records, this mechanistic understanding underpins ongoing clinical development across AML, MDS, glioma, and cholangiocarcinoma.
Co-occurring mutations identified as clinically relevant in retrieved results include FLT3, IDH2 (arising in the same clone or emerging under selective pressure), and RAS/MAPK pathway alterations. FLT3 and IDH1 co-mutations occur in approximately 5–10% of AML cases and represent a high-risk subgroup with reduced single-agent IDH1 inhibitor efficacy.
2-HG is an oncometabolite produced by mutant IDH1 and IDH2 enzymes through a neomorphic reduction of alpha-ketoglutarate. Its accumulation competitively inhibits alpha-KG-dependent dioxygenases — enzymes responsible for DNA and histone demethylation — locking myeloid progenitor cells in an undifferentiated, proliferative state that drives leukemogenesis in IDH1-mutant AML.
Olutasidenib’s Clinical Profile and FDA Approval Data
Olutasidenib (FT-2102), developed by Forma Therapeutics, received FDA approval in December 2022 for adult patients with relapsed or refractory IDH1-mutated AML — a milestone grounded in a phase 2 primary analysis that demonstrated a CR/CRh rate of 35%, a median overall survival of 11.6 months, and a median duration of CR/CRh of 25.9 months at the approved dose of 150 mg twice daily.
Olutasidenib 150 mg twice daily achieved a CR/CRh rate of 35% in patients with relapsed/refractory IDH1-mutated AML, with a median overall survival of 11.6 months and a median duration of remission of 25.9 months, supporting FDA approval in December 2022.
The phase 1/2 DRIVE trial (de Botton et al., 2023) evaluated olutasidenib as a single agent or combined with azacitidine in IDH1-mutated myeloid malignancies. Grade 3 or higher adverse events occurred in 56% of patients in the single-agent arm, with nausea being the most common treatment-emergent adverse event across the broader safety population at 52%. Differentiation syndrome was observed in 13% of patients treated with olutasidenib monotherapy.
Pharmacokinetically, olutasidenib is a CYP3A4 inducer at therapeutic doses, with oral bioavailability supporting the twice-daily regimen. This CYP3A4 induction carries clinical drug-drug interaction implications that distinguish its management profile from ivosidenib, which is dosed once daily. Patents filed by Forma Therapeutics (US20230078450; WO2024081773) confirm that 2-HG suppression serves as a pharmacodynamic biomarker for monitoring therapy, with early 2-HG reduction correlating with clinical response.
Analyse olutasidenib patent filings and clinical trial data in real time with PatSnap Eureka.
Explore IDH1 Inhibitor Data in PatSnap Eureka →How Olutasidenib Differs from Ivosidenib: Selectivity, Structure, and Safety
Olutasidenib and ivosidenib both inhibit mutant IDH1 at the allosteric site, preventing the conformational change required for NADPH-dependent 2-HG production — but their pharmacological profiles diverge in ways that matter clinically. Olutasidenib exhibits over 100-fold selectivity for mutant IDH1 versus wild-type IDH1 at therapeutic concentrations, a ratio that exceeds that of ivosidenib and is considered a key differentiating feature by Forma Therapeutics’ patent estate and published pharmacology data from Choe et al. (2022).
Olutasidenib exhibits over 100-fold selectivity for mutant IDH1 versus wild-type IDH1 at therapeutic concentrations, a higher mutant-selective ratio than ivosidenib, as reported in nonclinical and clinical pharmacology studies by Choe et al. (2022).
Structural analyses reveal that olutasidenib and ivosidenib occupy distinct but overlapping binding poses at the allosteric site of mutant IDH1. This structural divergence translates into differences in allele coverage: olutasidenib demonstrates activity across multiple IDH1R132 variants (R132C, R132H, R132S, R132G, R132L), and its distinct binding kinetics relative to ivosidenib have been characterised in published pharmacology literature as potentially relevant to the resistance landscape. According to data published in Nature-affiliated journals, these structural distinctions are increasingly informing next-generation inhibitor design.
“Olutasidenib exhibits over 100-fold selectivity for mutant IDH1 versus wild-type IDH1, with distinct binding kinetics relative to ivosidenib — a pharmacological differentiation with direct implications for tolerability and resistance.”
The safety profiles of the two agents diverge on differentiation syndrome rates: differentiation syndrome occurred in 13% of olutasidenib-treated patients versus 3.9% in the ivosidenib pivotal trial (DiNardo et al., 2019). This difference may reflect the higher mutant-IDH1 selectivity of olutasidenib driving more complete 2-HG suppression and, consequently, more pronounced blast differentiation. Grade 3 or higher adverse events occurred in 56% of olutasidenib patients in the DRIVE trial.
The ivosidenib pivotal trial (DiNardo et al., 2019) reported an overall response rate of 41.6% and a CR/CRh rate of 30.4% in relapsed/refractory IDH1-mutated AML — numerically lower than olutasidenib’s CR/CRh rate of 35%, though cross-trial comparisons must account for differences in patient populations and trial design. Both agents are approved by the FDA for IDH1-mutated relapsed/refractory AML, and their distinct pharmacological profiles are informing sequencing and combination strategies.
Resistance Mechanisms and the Next-Generation IDH1 Inhibitor Pipeline
Acquired resistance to IDH1 inhibitors is a defining challenge in the relapsed/refractory setting, and the mechanisms identified across retrieved results are converging into a coherent resistance taxonomy. Second-site IDH1 mutations — particularly S280F and Q316E — disrupt drug binding without abolishing the neomorphic enzyme activity, allowing continued 2-HG production in the presence of the inhibitor. Co-occurring IDH2 mutations in the same clone provide an alternative route to 2-HG synthesis, bypassing IDH1 inhibition entirely. RAS/MAPK pathway activation represents a third, non-metabolic resistance mechanism that drives blast proliferation independently of 2-HG.
Acquired resistance to IDH1 inhibitors olutasidenib and ivosidenib in AML involves second-site IDH1 mutations (S280F, Q316E) that disrupt drug binding, co-occurring IDH2 mutations that activate an alternative 2-HG production pathway, and upregulation of RAS/MAPK signalling.
In patients with IDH1-mutant AML previously treated with ivosidenib, olutasidenib demonstrated limited activity, with response rates substantially lower than in IDH1-inhibitor-naive patients (DiNardo et al., 2023). Serial ctDNA and 2-HG monitoring identified persistent on-target 2-HG suppression in some non-responders, indicating that resistance in these patients operates through mechanisms beyond IDH1 re-activation — including co-occurring RAS and receptor tyrosine kinase mutations. This finding has direct implications for sequencing strategies and underscores that cross-resistance between the two approved IDH1 inhibitors is substantial.
Next-generation IDH1 inhibitors are being developed to address resistance to both ivosidenib and olutasidenib, particularly targeting the S280F second-site resistance mutation and allele-switching to IDH2 mutation. Compounds with type II binding characteristics or dual IDH1/IDH2 activity may retain activity in the resistant setting. The IDH1 inhibitor pipeline increasingly includes compounds optimised for CNS penetration for glioma applications. (Kats et al., 2023; Nanjing Joyo Biotech, WO2022109472)
The patent landscape reflects this resistance-focused innovation. Nanjing Joyo Biotech (WO2022109472) has filed patents covering IDH1/IDH2 dual inhibitors designed to block the alternative metabolic escape pathway activated upon single-agent IDH inhibition. Syros Pharmaceuticals (WO2019157325) has explored CDK7 inhibitor combinations with IDH1 inhibitors. According to data indexed by EPO Espacenet, the assignee landscape in IDH1 inhibitor patents spans Forma Therapeutics, Agios Pharmaceuticals, Nanjing Joyo Biotech, and Syros Pharmaceuticals, reflecting a competitive pipeline beyond the two currently approved agents.
Olutasidenib retains activity against a subset of ivosidenib-resistant mutations, particularly those not involving the direct drug-binding interface (Harding et al., 2022). However, both agents are susceptible to RAS/MAPK-driven resistance, suggesting a rationale for combination with MEK inhibitors as a future strategy.
Combination Strategies: Azacitidine, Venetoclax, and Triplet Regimens
The combination of olutasidenib with azacitidine represents the most clinically advanced combination strategy and is grounded in a mechanistic complementarity: azacitidine-mediated DNMT inhibition independently targets DNA methylation pathways dysregulated in IDH1-mutant AML, reducing the epigenetic threshold required for IDH1 inhibitor-driven differentiation. Tiong et al. (2022) demonstrated that hypomethylating agent pretreatment alters the epigenetic landscape of IDH1-mutant AML cells in a manner that potentiates the differentiation-inducing effects of IDH1 inhibitor therapy.
In the phase 1b/2 study reported by Watts et al. (2023), 78 patients with IDH1-mutated myeloid malignancies were treated with olutasidenib plus azacitidine. Among patients with newly diagnosed AML, the CR/CRh rate was 74%. Among patients with relapsed or refractory AML, the CR/CRh rate was 41%. Among patients with MDS, the overall response rate was 62%. The most common treatment-emergent adverse event in the safety population was nausea at 52%.
In a phase 1b/2 study of olutasidenib combined with azacitidine in IDH1-mutated myeloid malignancies, the CR/CRh rate was 74% in newly diagnosed AML, 41% in relapsed/refractory AML, and the overall response rate was 62% in MDS, with nausea as the most common adverse event (52%).
The BCL-2 inhibitor venetoclax adds a third mechanistic dimension: targeting the apoptotic resistance maintained by BCL-2 overexpression in IDH1-mutant blast cells, complementing the differentiation-inducing effect of IDH1 inhibition. Forma Therapeutics (WO2022056379) has filed patents covering the olutasidenib plus venetoclax combination, citing synergistic activity in IDH1-mutant AML cell lines and primary patient samples. Agios Pharmaceuticals (WO2021142375) holds parallel intellectual property covering IDH inhibitor plus BCL-2 inhibitor combinations, including ivosidenib with venetoclax.
Map the full olutasidenib combination patent landscape and identify emerging assignees with PatSnap Eureka.
Search Combination IP in PatSnap Eureka →A triplet combination of olutasidenib, azacitidine, and venetoclax has been evaluated in a single-arm study (Stahl et al., 2023). Preliminary results demonstrated deep remissions including MRD-negative CR in heavily pre-treated patients with IDH1-mutated AML, including those who relapsed following prior IDH1 inhibitor therapy, with manageable tolerability using growth factor support. FLT3 co-mutation is also being addressed in combination strategies: preclinical studies combining olutasidenib or ivosidenib with FLT3 inhibitors gilteritinib or midostaurin demonstrated synergistic anti-leukemic activity and enhanced differentiation induction (Swaminathan et al., 2022). According to WIPO patent filings, the breadth of combination-focused intellectual property in the IDH1 inhibitor space continues to expand, reflecting the field’s recognition that single-agent activity will be insufficient for durable remissions in most relapsed patients.
Emerging combination rationales in the IDH1 inhibitor pipeline
- Olutasidenib + azacitidine: Dual epigenetic targeting; CR/CRh 41% in R/R AML, 74% in newly diagnosed AML (Watts et al., 2023)
- Olutasidenib + venetoclax: IDH1 inhibition plus BCL-2-mediated apoptosis induction; synergistic in preclinical IDH1-mutant models (Forma Therapeutics WO2022056379)
- Olutasidenib + azacitidine + venetoclax (triplet): MRD-negative CR observed in heavily pre-treated patients including post-IDH1 inhibitor relapse (Stahl et al., 2023)
- IDH1 inhibitor + FLT3 inhibitor: Synergistic anti-leukemic activity in FLT3/IDH1 co-mutated AML (5–10% of cases); gilteritinib and midostaurin evaluated preclinically (Swaminathan et al., 2022)
- IDH1 inhibitor + MEK inhibitor: Proposed strategy to address RAS/MAPK-driven resistance to both ivosidenib and olutasidenib (Harding et al., 2022)
- IDH1/IDH2 dual inhibition: Designed to block IDH2-mediated escape in IDH1 inhibitor-resistant clones (Nanjing Joyo Biotech WO2022109472)